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Abstract 
Epigenetic changes include the addition of a methyl group to the 5’ carbon of 
the cytosine ring, known as DNA methylation, which results in the generation of the 
fifth DNA base, namely 5-methylcytosine. During active or passive demethylation, an 
intermediate modified base is formed, 5-hydroxymethylcytosine. 
We have currenlty quantified 5-methylcytosine and 5-hydroxymethylcytosine 
in the liver and brain of mice treated with cocaine or heroin, using liquid 
chromatography/tandem mass spectrometry (LC-MS/MS). Our results show that 
global 5-methylcytosine levels are not affected by heroin or cocaine administration, 
neither in the liver nor in the brain. However, 5-hydroxymethylcytosine levels are 
reduced in the liver following cocaine administration, while they are not affected by 
cocaine in the brain or by heroin administration in the liver and brain.  
Elucidation of the epigenetic phenomena that take place with respect to drug 
abuse and addiction, via quantitative analysis of different modified bases, may 
enable a better understanding of the underlying mechanisms and may lead to more 
personalized and effective treatment options.  
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1. Introduction 
The field of epigenetics has received increasing scientific interest during the 
last 15 years. Epigenetic modifications, such as DNA methylation and histone 
modifications (phosphorylation and acetylation), are heritable and alter the 
phenotype while the DNA sequence remains unaffected. These modifications result 
in changes in chromatin structure and DNA accessibility and therefore alter gene 
expression (Handy et al., 2011). 
During DNA methylation, a methyl group is added to the carbon at the 5’ 
position of the cytosine ring forming the fifth DNA base, 5-methylcytosine (5-mC). 
The preferred sites for DNA methylation are CpG dinucleotide rich regions of the 
genome, called CpG islands. DNA methylation at gene promoter sites causes 
transcriptional silencing and affects the expression of genes that play a role in 
different biological processes, such as cell adherence, cell cycle, DNA repair, 
detoxification and apoptosis (Fragou et al., 2007, Richardson, 2003). Therefore, 
epigenetic phenomena are involved in various disease states and processes, 
including drug addiction (Schmidt et al., 2013, Hope et al., 2013, Fragou et al., 2013, 
Kovatsi et al., 2011, Fragou et al., 2011). 
Histone modifications and DNA methylation of specific genes play a significant 
role in the underlying mechanisms of drug addiction and abuse (Maze et al., 2011, 
Sun et al., 2012, Nestler, 2014, Nielsen et al., 2012b, Shirazi et al., 2013). Methylation 
of the AP-1 (Activator protein 1) and SP1 (Specificity protein 1) binding sites and 
subsequent regulation of PKCe (Protein kinase C epsilon) expression and 
transcription is induced in the fetal rat heart by maternal exposure to cocaine 
(Meyer et al., 2009, Zhang et al., 2007, Zhang et al., 2009), while alterations in the 
global methylation status are observed in hippocampal neurons (Novikova et al., 
2008). Furthermore, it has been recently found that cocaine represses protein 
phosphatase-1Cβ in rat brain through DNA methylation. This process may affect 
memory and learning and may play a role in behavioural changes induced by the 
drug (Pol Bodetto et al., 2013). Hypermethylation of genes and alterations in gene 
expression in the brain is thought to play a crucial role in drug addiction processes 
(Nielsen et al., 2009, Carouge et al., 2010, Yoo et al., 2012, Gorelick et al., 2005). 
Even abstinence from cocaine self-administration has been shown to induce changes 
in the DNA methylation status of CpG islands in the promoter region of the Sox10 
gene in the brain (Nielsen et al., 2012a). Furthermore, vulnerability to drug addiction 
and in particular heroin, has been associated with OPRM1 (Opioid receptor mu 1) 
gene expression (Nielsen et al., 2009). Hypermethylation of the promoter region of 
the gene in former heroin addicts reduced the expression of OPRM1 in lymphocytes, 
and this mechanism could explain a predisposal to heroin addiction vulnerability 
(Kovatsi et al., 2011, Nielsen et al., 2009, Yuferov et al., 2010, Bart et al., 2004). Since 
epigenetic phenomena are reversible, demethylating agents could be used as 
therapeutic tools against opioid addiction and this seems to be a promising field 
towards the development of new therapeutic strategies (Kovatsi et al., 2011, Fragou 
et al., 2011, Kouidou et al., 2010).  
In a recent study, the global DNA methylation levels in the liver and brain of 
mice dosed with cocaine and heroin were evaluated (Fragou et al., 2013). This study 
revealed tissue specific differences in the global methylation status between brain 
and liver. However, no difference in the overall content of % 5-MedC was observed 
between dosed and control animals in either tissue (Fragou et al., 2013). This 
observation could be explained by the triggering of demethylation as a repair 
mechanism. Therefore, monitoring of the demethylation process could elucidate the 
underlying mechanism responsible for these findings and could provide a useful 
insight into the processes involved in drug addiction. 
A modified base of increasing scientific interest is 5-hydroxymethylcytosine (5-
hmC), which is considered an intermediate product in the process of DNA 
demethylation, either active or passive. In the active demethylation process, 5-mC is 
oxidized to 5-hmC. 5-hmC is subsequently converted to cytosine with the help of 
DNA methyltransferases, or is deaminated to 5-hydroxymethyluracil, which is then 
removed by base excision pathways. Another suggested pathway involves the 
further oxidation of 5-hmC to 5-formylcytosine (5-fC) by TET proteins and then to 5-
carboxylcytosine (5-caC). Removal of 5-caC is achieved either by decarboxylation or 
base excision pathways. In the passive demethylation process, conversion of 5-mC to 
5-hmC does not allow maintenance of the methylation since DNA methyltransferase 
1, an enzyme responsible for propagation of methylation patterns, cannot copy 5-
hmC (Pfeifer et al., 2013). 
5-hmC has only recently been studied in relation to various diseases, such as 
cancer and neurodegenerative disorders. A decrease in global 5-hmC levels has been 
reported in melanoma and liver, kidney, colon, brain, lung, prostate and breast 
cancer.  
Global 5-hmC levels can be used as a prognostic, diagnostic or predictive 
biomarker. The global levels of 5-hmC have been recently used to evaluate the 
effectiveness of anticancer agents (Laird et al., 2013). Furthermore, a global increase 
in 5-hmC levels in the cartilage of patients suffering from osteoarthritis, compared to 
normal tissue, was reported (Taylor et al., 2014). In a recent study on mice with 
fragile X-associated tremor/ataxia syndrome, it was shown that overall cerebellar 5-
hmC levels were increased compared to wild type animals and that the genomic 
regions with an altered 5-hmC profile were the ones that are associated with 
transcription factors and genes that play an important role in neuronal function and 
development (Yao et al., 2014). 
Research on epigenetics in drug abuse and addiction has mainly focused until 
today on the methylation status of specific genes, rather than global DNA 
methylation and therefore information on the global picture is limited (Tian et al., 
2012). Furthermore, 5-hmC, which is a modified base receiving increasing scientific 
interest, has only recently been studied in the context of drug abuse (Jayanthi et al., 
2013). By elucidating the global epigenetic phenomena that underlie drug addiction 
or the adverse effects of drug abuse, we hope to be able to provide personalised 
therapeutic strategies, based on the selective reversal of these epigenetic 
alterations.  
We have currently determined, by LC-MS/MS, two modified bases, namely 5-
mdC and 5-hmdC, in the liver and brain of mice that received heroin, in a chronic 
‘intermittent’ escalating dose paradigm and cocaine, in a chronic “binge” escalating 
dose paradigm. For the purpose of our study, we have used high-end methodology, 
capable of distinguishing 5-mdC from 5-hmdC (which have a similar chemical 
structure and cannot always be separated effectively) and of quantifying both at very 
low levels. 
 
2. Materials and Methods 
2.1. Animals and drug administration paradigms 
The animals used and the chronic heroin/cocaine dosing scheme have been 
previously described in detail (Fragou et al., 2013). 
Briefly, thirty six eight-week old, male C57BL⁄6J mice (B & K Universal, Hull, 
UK), were used in the current study, which was conducted according to the protocols 
approved by the Home Office (Animals Act 1986) UK and the European Community 
Council Directive of the 24th Nov 1986 (86 ⁄ 609 ⁄ EEC). 
For the heroin experiment, eighteen animals were divided into two groups 
(n=9/group) and received intraperitoneal (i.p.) injections of either saline or heroin 
for 7 days. Two intraperitoneal injections of saline or heroin were administered daily 
(17.00 and 09.00 h), in accordance to previous opioid administration protocols 
(Bailey et al., 2010, Muller and Unterwald, 2004, Spanagel, 1995). The heroin-treated 
animals received 2 × 1 mg/kg/injection on day 1, 2 × 2 mg/kg/injection on days 2 and 
3, 2 × 4 mg/kg/injection on days 4 and 5, and 2 × 8 mg/kg/injection on days 6 and 7. 
This chronic ‘intermittent’ escalating dose paradigm was used to mimic a common 
pattern of self-administration in human heroin abusers (Kreek et al., 2002). Animals 
were killed by decapitation following a 30-sec exposure to CO2 and tissues of 
interest, i.e., brain and liver, were removed and snap frozen in liquid nitrogen. 
For the cocaine experiment, another eighteen C57BL/6J mice, divided into two 
groups (n=9/group) received intraperitoneal (i.p.) injections of either saline or 
cocaine for 14 days. An escalating dose ‘binge’ administration paradigm was used, as 
previously described by Bailey et al. (Bailey et al., 2005, Bailey et al., 2007, Bailey et 
al., 2008, Bailey et al., 2005, Schlussman et al., 2005), to mimic a common pattern of 
self-administration in human cocaine abusers (Tsukada et al., 1996). The cocaine-
treated animals received 3 × 15 mg/kg/day on days 1–4, 3 × 20 mg/kg/day on days 
5–8, 3 × 25 mg/kg/day on days 9–12, and 3 × 30 mg/kg/day on days 13 and 14. 
Animals were killed by decapitation following exposure to CO2 and tissues of interest 
(brain and liver) were dissected and immediately snap frozen in liquid nitrogen. 
Tissues were stored at -80°C until use. 
 
2.2. DNA Extraction & Hydrolysis 
Mice liver and brain DNA isolation was performed as previously described 
using the Qiagen DNA Buffer set and the Qiagen genomic tip (Fragou et al., 2013). 
Briefly, the tissues were homogenized in Buffer G2 and then incubated with RNase A, 
RNase T1 and Proteinase K. The resulting homogenate was loaded onto the Qiagen 
genomic tip, which was previously equilibrated with Buffer QBT. The tip was washed 
with Buffer QC and the DNA was subsequently eluted with Buffer QF. Enzymatic 
hydrolysis of DNA was performed as described by Hu et al. (Hu et al., 2013), spiked 
with d3-5-mdC and d3-5-hmdC (Toronto Research Chemicals) as internal standards, 
followed by LC-MS/MS analysis. 
 
2.3. Analysis of 5-mdC and 5-hmdC using LC-MS/MS  
Concentrations of 5-mdC and 5-hmdC in DNA were measured using a recently 
validated LC-MS/MS method by Hu et al. (Hu et al., 2014, manuscript submitted for 
publication) with some modifications. LC-MS/MS analysis was performed using an 
Agilent 1100 series HPLC system interfaced with a API 3000 triple quadrupole mass 
spectrometer with electrospray ionization (ESI) source (Applied Biosystems). Briefly, 
20 L of prepared DNA sample were initially cleaned up using an automatic system, 
which consisted of a switching valve (2-position microelectric actuator from Valco) 
and a C18 trap column (33 × 2.1 mm i.d., 5 m, ODS-3, Inertsil). The mobile phase 
consisted of: (A) 3% (v/v) methanol (MeOH)/1 mM ammonium acetate (AA) and (B) 
75% (v/v) MeOH/1 mM AA, at a flow rate of 200 L/min. The gradient program 
started with 100% A held for 4.7 min, 100% A to reach 100% B at 4.8 min, 100% B 
held for 1.2 min, 100% B to reach 100% A at 6.1 min and held for 8.9 min. After 
automatic sample cleanup, the sample was automatically transferred onto a C18 
analytical column (150 × 2.1 mm i.d., 5 m, ODS-3, Inertsil). The column was washed 
with a mobile phase of (C) 5% (v/v) MeOH/1 mM AA and (D) 100% of 50 % (v/v) 
MeOH/1 mM AA. The gradient program started with 100% C held for 6.0 min, 100% 
C to reach 100% D at 11.0 min, 100% D to reach 100% C at 11.6 min and held for 3.4 
min. The total run time was 15 min. 
The samples were analyzed in the positive ion multiple reaction monitoring 
(MRM) mode, and the transitions of the precursors to the product ions were as 
follows: 5-mdC (m/z 242 → 126 and 242 → 109), d3-5-mdC (m/z 245 → 129), 5-hmdC 
(m/z 258 → 142 and 258 → 124) and d3-5-hmdC (m/z 261→145). The dwell times per 
channel were set at 100 ms for both the analytes and the internal standards. The 
optimized ESI-MS/MS conditions were as follows: needle voltage, 5000 V; nebulizer 
gas flow, 10; curtain gas flow, 10; turbo gas flow, 8 heated at 450 °C; collision-
assisted-dissociation gas flow, 4; declustering potential voltage, 15 V for 5-mdC/d3-5-
mdC and 20 V for 5-hmdC/d3-5-hmdC; focusing potential voltage, 150 V for 5-
mdC/d3-5-mdC and 130 V for 5-hmdC/d3-5-hmdC; collision energy, 15 V (m/z 
242→126) and 50 V (m/z 242 → 109) for 5-mdC, and 15 V for d3-5-mdC, 20 V (m/z 
258 → 142) and 35 V (m/z 258 → 124) for 5-hmdC, and 20 V for d3-5-hmdC. Peak 
widths were set at 0.7 Th (full width at half-maximum) for both Q1 and Q3. The limits 
of detection were 0.012 ng/mL on column (1.0 fmol in a 20 μL injection volume) and 
0.2 ng/mL on column (16 fmol) for 5-mdC and 5-hmdC, respectively. 
 
2.4. Statistical Analysis 
All statistical analyses were carried out using the SPSS software V. 18. The 
Mann-Whitney U-test was used for group comparison, with a confidence interval of 
95 %. Values are expressed as mean ± SD (n=9). 
 
3. Results 
Fig. 1 shows a representative LC-MS/MS chromatogram for 5-mdC and 5-hmdC 
and their stable isotope-labeled internal standards of a hydrolysate from saline 
treated mice brain DNA. Data obtained from the two different control groups 
showed that the 5-mdC levels ranged between 3.4% and 3.8 % in both tissues, 
whereas the 5-hmdC levels were significantly lower, 0.2-0.6 % (Tables 1 & 2). 
Our results showed that chronic, escalating dose, heroin administration did not 
affect 5-mdC or 5-hmdC levels in the brain and liver (Table 1).  
Chronic, “binge”, escalating dose cocaine administration did not affect 5-mdC 
levels, neither in the brain nor the liver (Table 2). Nevertheless, it induced a 
statistically significant decrease of 5-hmdC levels in the liver (p=0.000), while no 
effect on 5-hmdC levels was observed in the brain of cocaine-treated animals (Table 
2). 
When the two different tissues were compared, the 5-mdC levels were always 
higher in brain, compared to liver, not only in the two control groups (cocaine 
control group: brain 3.7%, liver 3.6%, p=0.0050 and heroin control group: brain 3.8%, 
liver 3.4%, p=0.000), but also in the drug-treated groups (cocaine-treated group: 
brain 3.7%, liver 3.5%, p=0.000 and heroin treated group: brain 3.9%, liver 3.4%, 
p=0.000). 
Similar findings were observed for 5-hmdC. Brain was in every case the tissue 
where this modified base was more abundant (cocaine control group: brain 0.6%, 
liver 0.2%, p=0.000; heroin control group: brain 0.3%, liver 0.2%, p=0.000; cocaine-
treated group: brain 0.6%, liver 0.1%, p=0.000; heroin-treated group: brain 0.3%, 
liver 0.2%, p=0.000). 
 4. Discussion 
The LC-MS/MS method used in this study is precise and reliable (Hu et al., 
2013). The stable isotope-labeled internal standard method enhances accuracy for 
the determination of the 5-mdC and 5-hmdC content. There is limited information 
on global DNA methylation and hydroxymethylation induced by drug abuse and 
addiction. Most of the studies published until today, focus on specific genes (Barros 
et al., 2013), with a special interest in the OPRM1 (Nielsen et al., 2009, Yuferov et al., 
2010, Nielsen et al., 2010). In one case it was reported that the OPRM1 gene was 
significantly hypermethylated not only in blood, but also in sperm-derived DNA, 
suggesting that this epigenetic phenomenon may be the mechanism by which opioid 
abuse and dependence phenotypes are transferred to the next generation (Chorbov 
et al., 2011). In another study, it was shown that in the brain of chronic opiate 
addicts, enhanced methylation of the OPRM1 DNA hinders the μ-opioid receptor 
upregulation. Furthermore, the researchers reported that this epigenetic mechanism 
is triggered via a nucleotide exchange which introduces a new methylation site 
concluding that genetic alterations may lead to epigenetic modifications with 
functional consequences (Oertel et al., 2012).  
Although DNA methylation in drug addiction has received increasing scientific 
interest over the last years, 5-hmC has only recently been studied in this context by a 
scientific group that focused on methamphetamine-induced alterations in DNA 
methylation and hydroxymethylation in the striatal glutamate receptor promoter 
sequences (Jayanthi et al., 2013). It was reported that methamphetamine causes a 
decrease in the methylation and hydroxymethylation of the GluA1 and GluA2 
promoter sequences. The impact of these changes on receptor gene expression and, 
as a result, on behaviour is not clear, although it is unlikely that they are responsible 
for the downregulation of striatal glutamate receptors observed following chronic 
methamphetamine use (Jayanthi et al., 2013). 
In the current study, we have determined global DNA methylation and 
hydroxymethylation in brain and liver of mice following chronic heroin and cocaine 
administration. We have focused on the global picture and not on specific genes and 
we have targeted both modified nucleotides.   
According to our findings, the administration of heroin did not affect 5-mdC or 
5-hmdC, in neither of the tissues examined. These findings are in agreement, as far 
as 5-mdC is concerned, with the findings of our previous study (Fragou et al., 2013), 
where brain and liver samples from cocaine- and heroin-treated mice were analyzed 
by HPLC-DAD. However, the HPLC-DAD method used in our previous study could not 
discriminate between 5-mdC and 5-hmdC which might co-elute together with other 
modified bases such as 5-formylcytosine and 5-carboxycytosine, therefore no data 
on 5-hmdC were available from that study.  
The measurement of 5-mdC alone is not sufficient to determine changes in the 
methylation status, i.e. changes in methylation might by slipping unobserved 
because they might be compensated by protective mechanisms which convert 5-
mdC to 5-hmdC. Therefore, the simultaneous determination of 5-mdC and 5-hmdC is 
important to determine a clear and accurate picture of the methylation state of a 
tissue.  
In the current study, chronic heroin administration had no effect on the 5-mdC 
and 5-hmdC content of liver or brain, and therefore we can safely conclude that 
there was no change in the overall methylation status in these tissues following 
heroin administration.  
5-mdC was not affected by cocaine in either tissue. The fact that chronic 
cocaine administration had no effect on 5-mdC levels in the liver and brain was 
anticipated based on the findings of our previous study, according to which the 
particular cocaine administration paradigm left the 5-mdC levels unaffected in both 
tissues studied.  
On the other hand, we found that chronic cocaine administration decreased 5-
hmdC specifically in the liver but not the brain. Indeed, decreased 5-hmC has been 
associated with hepatocellular carcinomas and downregulation of the expression of 
TET1 proteins, with tumor size and poor survival and with alpha-fetoprotein levels 
(Liu et al., 2013). Moreover, Ivanov et al. (Ivanov et al., 2013) suggest that 5-hmC 
plays a role in liver function and development and that it might be responsible for 
inter-individual differences in drug metabolism and toxicity. Thus, based on the 
aforementioned evidence and given that chronic cocaine administration in the 
present study induced severe liver toxicity, we propose that the reduction in 5-hmdC 
levels in the liver could be the underlying mechanism for liver toxicity induced by 
chronic cocaine administration (Ivanov et al., 2013). 
In our study, the livers of cocaine-treated animals exhibited regions of necrosis 
and intense eosinophilia (Fig. 2). Furthermore, their % weight, relative to body 
weight, was significantly higher, when compared to the saline treated animals (6.12 
± 0.50% vs 4.27 ± 0.26%, p < 0.001) (Fragou et al., 2013).  
The higher 5-mdC and 5-hmdC content in brain, compared to liver, currently 
reported, is in agreement with previous findings (Khare et al., 2012, Unterberger et 
al., 2009, Song et al., 2011) and has been reported both in rats and mice 
(Shimabukuro et al., 2006, Kriaucionis and Heintz, 2009), as well as in humans (Fuke 
et al., 2004, Nestor et al., 2012). This difference in tissue 5-hmdC levels has been 
attributed to differences in 5-hmdC loss in passive demethylation pathways. 
Therefore, tissues with a relatively low proliferation rate (such as brain) don’t lose as 
much as 5-hmC and therefore, have a higher 5-hmC content. Differences in 5-hmdC 
content are likely to affect gene transcription, altering the phenotype of a tissue. For 
example, breast cancer cell lines exhibit reduced levels of global 5-hmC, concomitant 
with extensive promoter hypermethylation which has been shown to affect gene 
expression (Nestor et al., 2012). 
According to the same study, global 5-hmC levels do not correlate with global 
5-mC levels and inter-tissue variation is much larger for global 5-hmC, than for global 
5-mC. These findings suggest that although a gene may be transcribed at the same 
level in several tissues, great differences may be encountered in 5-hmC levels, 
depending on the tissue. Thus, quantitative analysis of 5-hmC is necessary (Nestor et 
al., 2012). 
The two control groups of animals used in the current study exhibited similar 
5-mC and 5-hmC levels in the two examined tissues, with the exception of 5-hmC 
levels in brain which were significantly higher in the control group used in the 
cocaine experiment. This deviation can be attributed to the fact that the control 
group of animals used in the cocaine experiment received 3 injections of saline per 
day, for 14 days, and was therefore subjected to more stress compared to the 
control group of animals used in the heroin experiment, that received 2 injections of 
saline per day, for 7 days. Studies have shown that the ten-eleven translocation (TET) 
proteins, which oxidize 5-mC to 5-hmC, are activated under stress conditions (Chia et 
al., 2011). 
Epigenetic mechanisms in addiction constitute a field with increasing scientific 
interest (Fragou et al., 2013). It was only recently shown that different factors (such 
as s-adenosylmethionine treatment) may modulate the development of addiction by 
modifying cocaine-induced DNA methylation. These epigenetic mechanisms have 
been proposed to be involved in different addiction vulnerability of different 
individuals (Anier et al., 2013). The complete unraveling of these mechanisms, which 
are reversible, promises the development of new therapeutic strategies for craving 
and relapse. Research is currently underway towards this direction (Tian et al., 2012) 
and a very recent study showed that the responsiveness to disulfiram (a known 
modulator of global methylation) administration for cocaine dependence is 
influenced by the patient’s genotype for the MTHFR gene, which is involved in 
methyl group supply. In this case, the authors implied that the patient’s genotype is 
important in customizing the treatment for cocaine dependence, specifically for each 
individual and therefore in increasing the efficacy of the treatment (Spellicy et al., 
2013). 
In conclusion, we have currently quantified the global 5-mdC and 5-hmdC DNA 
content in the liver and brain of mice treated with cocaine or heroin, by LC-MS/MS. 
Our results showed that there is no effect on the global methylation and 
hydroxymethylation status in the liver and brain of heroin-treated animals, nor in the 
brain of cocaine-treated animals. However, a reduction in the 5-hmdC DNA content 
in the liver of cocaine-treated mice was observed, which might be, at least partly, 
involved in the underlying mechanism of liver toxicity induced by cocaine. 
It is clear that the quantitative assessment both of 5-mdC, as well as 5-hmdC 
provides a better understanding of the epigenetic mechanisms underlying various 
disease states, including drug abuse and addiction. This insight might prove 
extremely useful in cases where a more effective, personalized treatment is 
required, or in cases where the reversal of the epigenetic phenomena that take place 
could lead to prevention and/or cure. 
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Figure legends 
Fig. 1. Chromatograms of 5-mdC and 5-hmdC in mouse brain DNA, as measured by 
LC-MS/MS. Multiple reaction monitoring transitions of m/z 242→126 (A) and m/z 
242→109 (B) for 5-mdC, m/z 245→129 (C) for d3-5-mdC, m/z 258→142 (D) and m/z 
258→124 (E) for 5-hmdC, and m/z 261→145 (F) for d3-5-hmdC. cps, counts per 
second. 
Fig. 2. Hepatic necrosis in the liver of a male C57BL/6 mouse administered an 
escalating dose of cocaine (viewed under a X10 objective).  
CV= Central Vein, E= Eosinophilic Cells, G= Ghost Cells, I=Inflammatory Infiltration 
 
 
  
Table 1: 5-mdC and 5-hmdC levels in the liver and brain of heroin treated and control 
mice. 
 
 
 
 
 
 
  
 Heroin 
 5-mdC Liver 5-mdC Brain 5-hmdC Liver 5-hmdC Brain 
 Control Treated Control Treated Control Treated Control Treated 
Mean (%) 3.4 3.4 3.8 3.9 0.2 0.2 0.3 0.3 
St. Dev.  0.1 0.1 0.2 0.2 0.01 0.01 0.03 0.03 
CV (%) 3.2 2.9 4.5 4.9 6.7 8.9 10.6 10.5 
p value (95%) 0.730 0.489 0.863 0.863 
Table 2: 5-mdC and 5-hmdC levels in the liver and brain of cocaine treated and 
control mice. 
 
 Cocaine 
 5-mdC Liver 5-mdC Brain 5-hmdC Liver 5-hmdC Brain 
 Control Treated Control Treated Control Treated Control Treated 
Mean (%) 3.6 3.5 3.7 3.7 0.2 0.1 0.6 0.6 
St. Dev.  0.1 0.1 0.1 0.1 0.01 0.004 0.02 0.03 
CV (%) 3.9 2.6 2.4 2.3 5.6 6.4 2.8 5.6 
p value (95%) 0.161 0.931 0.000 0.489 
 
Fig. 1 
Fig. 2 
Fig. 2. Hepatic necrosis in the liver of a male C57BL/6 
mouse administered an escalating dose of cocaine 
(viewed under a 10 objective). CV, central vein, E, 
eosinophilic cells, G, ghost cells, I, inflammatory 
infiltration  
